Travere Therapeutics
TVTX
TVTX
164 hedge funds and large institutions have $807M invested in Travere Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 57 increasing their positions, 52 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
164
Holders Change
-4
Holders Change %
-2.38%
% of All Funds
2.4%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
32
Increased
57
Reduced
52
Closed
36
Calls
$5.86M
Puts
$12.1M
Net Calls
-$6.28M
Net Calls Change
+$268K
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$54.2M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18.8M |
| 3 |
Renaissance Technologies
New York
|
+$9.77M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$9.37M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$8.66M |
Top Sellers
| 1 |
VA
VR Adviser
New York
|
-$23.5M |
| 2 |
Millennium Management
New York
|
-$18.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$13.6M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$8.45M |
| 5 |
SCM
Sio Capital Management
New York
|
-$7.91M |
